Bayer’s regorafenib kicks off brain cancer platform trial

Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.

GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international trial testing several therapies for patients with newly diagnosed and recurrent glioblastoma.